Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-human TIM-3 monoclonal antibody
- Development stage
- Unknown
- Lead developer
- The 2nd Affiliated Hospital of Harbin Medical University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-human TIM-3 monoclonal antibody is a research-grade biologic agent used to target and inhibit the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) receptor. TIM-3 is an immune checkpoint protein that plays a critical role in regulating adaptive and innate immune responses. In studies involving Guillain-Barré syndrome (GBS), such as those conducted at the Second Affiliated Hospital of Harbin Medical University, this antibody is utilized in vitro to investigate the modulation of T helper 17 (Th17) cells and the broader immunopathological mechanisms of the disease. By blocking TIM-3 signaling, researchers can observe changes in cytokine production and cellular activation, helping to clarify the role of this pathway in autoimmune-mediated peripheral nerve damage.
- Other names
- anti-TIM-3 antibodyanti-TIM3 antibodyanti-TIM 3 antibodyanti-TIM-3 mAbanti-TIM3 mAbanti-TIM 3 mAb
02
Targets
HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on anti-human TIM-3 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-human TIM-3 monoclonal antibody.